Generate a tailored SOP for Dr. Katherine Borden. Improve your application with a focused, well-structured draft.
Katherine Borden is a Professor of Pharmacology at Northwestern University's Feinberg School of Medicine. Her research primarily focuses on understanding the mechanisms by which dysregulated RNA metabolism contributes to cancer, specifically Acute Myeloid Leukemia (AML). Her pioneering work has demonstrated how cancer cells hijack RNA metabolism to alter gene expression and enhance tumor growth. Borden's laboratory has uncovered novel modes of gene regulation facilitated by the eukaryotic translation initiation factor eIF4E, which has been found to play a critical role in both nuclear and cytoplasmic RNA metabolism. This research has implications for the development of targeted therapies in cancer treatment. Borden's contributions to the field have been recognized through numerous awards, including being a Fellow of the Canadian Academy of Health Sciences and the Royal Society of Canada. She currently leads efforts in identifying combination therapies to target eIF4E in high-eIF4E AML patients, aiming to improve clinical outcomes and advance therapeutic strategies.
Administered by The Graduate School; focuses on Biomechanics, Imaging, Biomaterials, and Regenerative Medicine.